NVO Stock
-
Novo Nordisk Stock Falls on Disappointing CagriSema Trial Results
Novo Nordisk A/S (NVO) shares dropped pre-market after its experimental obesity drug, CagriSema, failed to meet its primary endpoint in a Phase 3 trial, impacting its competitive standing.
-
Novo Nordisk Stock Plunges After Alzheimer’s Trial Failure Spurs Turmoil and Fierce Market Competition
Novo Nordisk’s shares nosedived after its Alzheimer’s drug trial failed, intensifying investor concerns amid fierce competition and strategic shifts. The company faces mounting pressure from rivals, regulatory changes, and leadership upheaval, leaving its future direction under scrutiny.